Vascular Biology Center, Department of Medicine, Medical College of Georgia, Augusta University (B.H.A.).
Department of Cardiovascular Sciences, Houston Methodist Research Institute, TX (J.P.C.).
Circ Res. 2021 Jun 11;128(12):1944-1957. doi: 10.1161/CIRCRESAHA.121.318266. Epub 2021 Jun 10.
The prevalence of peripheral arterial disease (PAD) in the United States exceeds 10 million people, and PAD is a significant cause of morbidity and mortality across the globe. PAD is typically caused by atherosclerotic obstructions in the large arteries to the leg(s). The most common clinical consequences of PAD include pain on walking (claudication), impaired functional capacity, pain at rest, and loss of tissue integrity in the distal limbs that may lead to lower extremity amputation. Patients with PAD also have higher than expected rates of myocardial infarction, stroke, and cardiovascular death. Despite advances in surgical and endovascular procedures, revascularization procedures may be suboptimal in relieving symptoms, and some patients with PAD cannot be treated because of comorbid conditions. In some cases, relieving obstructive disease in the large conduit arteries does not assure complete limb salvage because of severe microvascular disease. Despite several decades of investigational efforts, medical therapies to improve perfusion to the distal limb are of limited benefit. Whereas recent studies of anticoagulant (eg, rivaroxaban) and intensive lipid lowering (such as PCSK9 [proprotein convertase subtilisin/kexin type 9] inhibitors) have reduced major cardiovascular and limb events in PAD populations, chronic ischemia of the limb remains largely resistant to medical therapy. Experimental approaches to improve limb outcomes have included the administration of angiogenic cytokines (either as recombinant protein or as gene therapy) as well as cell therapy. Although early angiogenesis and cell therapy studies were promising, these studies lacked sufficient control groups and larger randomized clinical trials have yet to achieve significant benefit. This review will focus on what has been learned to advance medical revascularization for PAD and how that information might lead to novel approaches for therapeutic angiogenesis and arteriogenesis for PAD.
外周动脉疾病(PAD)在美国的患病率超过 1000 万人,并且 PAD 是全球发病率和死亡率的重要原因。PAD 通常是由腿部大动脉硬化引起的阻塞引起的。PAD 的最常见临床后果包括行走时疼痛(跛行)、功能能力受损、休息时疼痛以及下肢远端组织完整性丧失,可能导致下肢截肢。PAD 患者的心肌梗死、中风和心血管死亡发生率也高于预期。尽管手术和血管内治疗取得了进展,但血管重建术可能无法缓解症状,并且由于合并症,一些 PAD 患者无法接受治疗。在某些情况下,由于严重的微血管疾病,缓解大导管动脉中的阻塞性疾病并不能确保完全肢体保存。尽管进行了几十年的研究,但改善远端肢体灌注的药物治疗的效果有限。尽管最近的抗凝剂(例如利伐沙班)和强化降脂(如 PCSK9 [前蛋白转化酶枯草溶菌素/克那霉 9]抑制剂)研究降低了 PAD 人群中的主要心血管和肢体事件,但肢体慢性缺血在很大程度上仍然对药物治疗有抵抗力。改善肢体预后的实验方法包括给予血管生成细胞因子(作为重组蛋白或基因治疗)以及细胞治疗。尽管早期的血管生成和细胞治疗研究很有希望,但这些研究缺乏足够的对照组,并且更大规模的随机临床试验尚未取得显著效果。这篇综述将重点介绍为 PAD 推进医学再血管化所学到的知识,以及这些信息如何为 PAD 的治疗性血管生成和动脉生成带来新的方法。